Effect of Statin Therapy on Cognitive Decline and Incident Dementia in Older Adults.
Effect of Statin Therapy on Cognitive Decline and Incident Dementia in Older Adults.
复制标题
他汀类药物治疗对老年人认知能力下降和事件痴呆的影响。
DOI:
10.1016/j.jacc.2021.04.075
复制
发表时间:
2021-06-29
影响因子:
24
通讯作者:
ASPREE Investigator Group
中科院分区:
文献类型:
--
作者:
Zhou Z;Ryan J;Ernst ME;Zoungas S;Tonkin AM;Woods RL;McNeil JJ;Reid CM;Curtis AJ;Wolfe R;Wrigglesworth J;Shah RC;Storey E;Murray A;Orchard SG;Nelson MR;ASPREE Investigator Group
BackgroundThe neurocognitive effect of statins in older adults remain uncertain.ObjectivesThe aim of this study was to investigate the associations of statin use with cognitive decline and incident dementia among older adults.MethodsThis analysis included 18,846 participants ≥65 years of age in a randomized trial of aspirin, who had no prior cardiovascular events, major physical disability, or dementia initially and were followed for 4.7 years. Outcome measures included incident dementia and its subclassifications (probable Alzheimer’s disease, mixed presentations); mild cognitive impairment (MCI) and its subclassifications (MCI consistent with Alzheimer’s disease, other MCI); and changes in domain-specific cognition, including global cognition, memory, language and executive function, psychomotor speed, and the composite of these domains. Associations of baseline statin use versus nonuse with dementia and MCI outcomes were examined using Cox proportional hazards models and with cognitive change using linear mixed-effects models, adjusting for potential confounders. The impact of statin lipophilicity on these associations was further examined, and effect modifiers were identified.ResultsStatin use versus nonuse was not associated with dementia, MCI, or their subclassifications or with changes in cognitive function scores over time (p > 0.05 for all). No differences were found in any outcomes between hydrophilic and lipophilic statin users. Baseline neurocognitive ability was an effect modifier for the associations of statins with dementia (p for interaction < 0.001) and memory change (p for interaction = 0.02).ConclusionsIn adults ≥65 years of age, statin therapy was not associated with incident dementia, MCI, or declines in individual cognition domains. These findings await confirmation from ongoing randomized trials.
登录
查看更多内容
DOI:
10.1056/nejmoa1805819
发表时间:
2018-10-18
期刊:
The New England journal of medicine
影响因子:
--
作者:
McNeil JJ;Wolfe R;Woods RL;Tonkin AM;Donnan GA;Nelson MR;Reid CM;Lockery JE;Kirpach B;Storey E;Shah RC;Williamson JD;Margolis KL;Ernst ME;Abhayaratna WP;Stocks N;Fitzgerald SM;Orchard SG;Trevaks RE;Beilin LJ;Johnston CI;Ryan J;Radziszewska B;Jelinek M;Malik M;Eaton CB;Brauer D;Cloud G;Wood EM;Mahady SE;Satterfield S;Grimm R;Murray AM;ASPREE Investigator Group
通讯作者:
ASPREE Investigator Group
影响因子:
4.6
作者:
Alsehli, Ahmed M.;Olivo, Gaia;Schioth, Helgi B.
通讯作者:
Schioth, Helgi B.
DOI:
10.1016/j.jalz.2011.03.004
发表时间:
2011-05
期刊:
Alzheimer's & dementia : the journal of the Alzheimer's Association
影响因子:
--
作者:
Jack CR Jr;Albert MS;Knopman DS;McKhann GM;Sperling RA;Carrillo MC;Thies B;Phelps CH
通讯作者:
Phelps CH
影响因子:
39.2
作者:
Odden MC;Pletcher MJ;Coxson PG;Thekkethala D;Guzman D;Heller D;Goldman L;Bibbins-Domingo K
通讯作者:
Bibbins-Domingo K
影响因子:
11
作者:
Haag, M. D. M.;Hofman, A.;Breteler, M. M. B.
通讯作者:
Breteler, M. M. B.